Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Growth Metrics

Others

Ligand Pharmaceuticals (LGNDZ) Work In Process (2023 - 2024)

Ligand Pharmaceuticals (LGNDZ) has disclosed Work In Process for 2 consecutive years, with $3.9 million as the latest value for Q4 2024.

Quarterly Work In Process rose 1911.79% to $3.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2024, up 1911.79% year-over-year, with the annual reading at $3.9 million for FY2024, 1911.79% up from the prior year.
Work In Process hit $3.9 million in Q4 2024 for Ligand Pharmaceuticals, up from $260000.0 in the prior quarter.
In the past five years, Work In Process ranged from a high of $3.9 million in Q4 2024 to a low of $195000.0 in Q4 2023.